At Sarepta, we’re committed to pursuing some of the world’s most debilitating, prevalent, and complex rare genetic diseases. Today, our primary focus is on Duchenne muscular dystrophy, limb-girdle muscular dystrophies, Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome A, and Charcot-Marie-Tooth disease.
SareptAssist is our patient support program designed to provide you with information to help you navigate the process of starting and staying on therapy. This program is available to patients in the United States.
Each member of our Patient Affairs Team brings passion, energy, and a deep commitment to their work every day whether they hail from our U.S. headquarters in Cambridge, Massachusetts, our offices in San Paolo, Brazil, or one of our locations in Europe.
Serving the rare disease community goes beyond developing precision genetic medicines. Corporate Giving is a core part of Sarepta’s mission.
Route 79, The Duchenne Scholarship Program, was created to support the post-secondary educational goals of students living with Duchenne.